These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
704 related articles for article (PubMed ID: 27270276)
1. Revisiting the Concept of Targeting Only Bacillus anthracis Toxins as a Treatment for Anthrax. Glinert I; Bar-David E; Sittner A; Weiss S; Schlomovitz J; Ben-Shmuel A; Mechaly A; Altboum Z; Kobiler D; Levy H Antimicrob Agents Chemother; 2016 Aug; 60(8):4878-85. PubMed ID: 27270276 [TBL] [Abstract][Full Text] [Related]
2. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Welkos S; Little S; Friedlander A; Fritz D; Fellows P Microbiology (Reading); 2001 Jun; 147(Pt 6):1677-1685. PubMed ID: 11390699 [TBL] [Abstract][Full Text] [Related]
3. A novel live attenuated anthrax spore vaccine based on an acapsular Bacillus anthracis Sterne strain with mutations in the htrA, lef and cya genes. Chitlaru T; Israeli M; Rotem S; Elia U; Bar-Haim E; Ehrlich S; Cohen O; Shafferman A Vaccine; 2017 Oct; 35(44):6030-6040. PubMed ID: 28342664 [TBL] [Abstract][Full Text] [Related]
4. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Hermanson G; Whitlow V; Parker S; Tonsky K; Rusalov D; Ferrari M; Lalor P; Komai M; Mere R; Bell M; Brenneman K; Mateczun A; Evans T; Kaslow D; Galloway D; Hobart P Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13601-6. PubMed ID: 15342913 [TBL] [Abstract][Full Text] [Related]
5. Immunization with a Recombinant, Pseudomonas fluorescens-Expressed, Mutant Form of Bacillus anthracis-Derived Protective Antigen Protects Rabbits from Anthrax Infection. Reed MD; Wilder JA; Mega WM; Hutt JA; Kuehl PJ; Valderas MW; Chew LL; Liang BC; Squires CH PLoS One; 2015; 10(7):e0130952. PubMed ID: 26207820 [TBL] [Abstract][Full Text] [Related]
6. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits. Wimer-Mackin S; Hinchcliffe M; Petrie CR; Warwood SJ; Tino WT; Williams MS; Stenz JP; Cheff A; Richardson C Vaccine; 2006 May; 24(18):3953-63. PubMed ID: 16530302 [TBL] [Abstract][Full Text] [Related]
7. Adenoviral Expression of a Bispecific VHH-Based Neutralizing Agent That Targets Protective Antigen Provides Prophylactic Protection from Anthrax in Mice. Moayeri M; Tremblay JM; Debatis M; Dmitriev IP; Kashentseva EA; Yeh AJ; Cheung GY; Curiel DT; Leppla S; Shoemaker CB Clin Vaccine Immunol; 2016 Jan; 23(3):213-8. PubMed ID: 26740390 [TBL] [Abstract][Full Text] [Related]
8. Development of Protective Immunity in New Zealand White Rabbits Challenged with Bacillus anthracis Spores and Treated with Antibiotics and Obiltoxaximab, a Monoclonal Antibody against Protective Antigen. Henning LN; Carpenter S; Stark GV; Serbina NV Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133571 [TBL] [Abstract][Full Text] [Related]
9. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Albrecht MT; Li H; Williamson ED; LeButt CS; Flick-Smith HC; Quinn CP; Westra H; Galloway D; Mateczun A; Goldman S; Groen H; Baillie LW Infect Immun; 2007 Nov; 75(11):5425-33. PubMed ID: 17646360 [TBL] [Abstract][Full Text] [Related]
10. The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions. Cote CK; Rossi CA; Kang AS; Morrow PR; Lee JS; Welkos SL Microb Pathog; 2005; 38(5-6):209-25. PubMed ID: 15925272 [TBL] [Abstract][Full Text] [Related]
11. A Bivalent Protein r-PAbxpB Comprising PA Domain IV and Exosporium Protein BxpB Confers Protection Against Majumder S; Das S; Somani VK; Makam SS; Kingston JJ; Bhatnagar R Front Immunol; 2019; 10():498. PubMed ID: 30941133 [TBL] [Abstract][Full Text] [Related]
12. Progress and novel strategies in vaccine development and treatment of anthrax. Chitlaru T; Altboum Z; Reuveny S; Shafferman A Immunol Rev; 2011 Jan; 239(1):221-36. PubMed ID: 21198675 [TBL] [Abstract][Full Text] [Related]
13. Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components. Mendelson I; Gat O; Aloni-Grinstein R; Altboum Z; Inbar I; Kronman C; Bar-Haim E; Cohen S; Velan B; Shafferman A Vaccine; 2005 Dec; 23(48-49):5688-97. PubMed ID: 16039760 [TBL] [Abstract][Full Text] [Related]
14. Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthrax. Skoble J; Beaber JW; Gao Y; Lovchik JA; Sower LE; Liu W; Luckett W; Peterson JW; Calendar R; Portnoy DA; Lyons CR; Dubensky TW Infect Immun; 2009 Apr; 77(4):1649-63. PubMed ID: 19168734 [TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. Staats HF; Alam SM; Scearce RM; Kirwan SM; Zhang JX; Gwinn WM; Haynes BF Infect Immun; 2007 Nov; 75(11):5443-52. PubMed ID: 17709410 [TBL] [Abstract][Full Text] [Related]
19. Generation of a novel chimeric PALFn antigen of Bacillus anthracis and its immunological characterization in mouse model. Suryanarayana N; Verma M; Thavachelvam K; Saxena N; Mankere B; Tuteja U; Hmuaka V Appl Microbiol Biotechnol; 2016 Oct; 100(19):8439-51. PubMed ID: 27364624 [TBL] [Abstract][Full Text] [Related]
20. Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor. Taft SC; Weiss AA Clin Vaccine Immunol; 2008 Jan; 15(1):71-5. PubMed ID: 18032590 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]